Prelude Therapeutics Incorporated (PRLD)
NASDAQ
Real-time Data
01:30 PM
Day's Range
6.4052 wk Range
0.9810Overview - PRLD - Prelude Therapeutics Incorporated
Key Statistics
Valuation
Enterprise Value
548.74M
P/E (Trailing)
‪-5.13‬
P/E (Forward)
‪-8.84‬
PEG Ratio
‪0.07‬
Price / Sales (TTM)
‪23.59‬
Price / Book
‪5.10‬
EV / EBITDA
‪-8.50‬
Profitability
Profit Margin
‪-269.74%‬
Operating Margin
‪-270.93%‬
Return on Assets
‪-27.15%‬
Return on Equity
‪-57.72%‬
Ownership
Shares Outstanding
63.01M
Float
22.06M
Short % of Shares Outstanding
‪14.59%‬
Held by Insiders
‪13.76%‬
Held by Institutions
‪76.45%‬
Price stats
Beta
‪0.93‬
50-Day Avg
‪4.73‬
200-Day Avg
‪3.40‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
3 analysts
Average price target
‪$ 8.00‬Shariah Compliance
Report Date: Feb 18, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - PRLD - Prelude Therapeutics Incorporated
Peers - PRLD - Prelude Therapeutics Incorporated
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- PRLDNASDAQPrelude Therapeutics Incorporated529.09MMarket Cap+80.84%52-week change-5.13P/E (Trailing)‪-269.74%‬Profit Margin
- ARGXNASDAQargenx SE American Depositary Receipt65.04BMarket Cap+34.86%52-week change39.69P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals Inc31.60BMarket Cap-87.81%52-week change41.15P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE29.28BMarket Cap+9.87%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S16.61BMarket Cap+23.98%52-week change19.38P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma, Inc.15.93BMarket Cap+41.98%52-week change-21.56P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBiomarin Pharmaceutical Inc.12.91BMarket Cap+12.29%52-week change180.27P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - PRLD - Prelude Therapeutics Incorporated
About
Prelude Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies targeting cancer. Its primary function is to advance the understanding of molecular diseases and design precision therapies aimed at challenging hematologic malignancies and solid tumors.…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
